ReviewCancers2019
Emerging Therapeutic Opportunities Based on Current Knowledge of Uveal Melanoma Biology.
Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 38 citations in OpenAlex.
- G protein GαThe Journal of biological chemistry · 2026Article
- A Review and Comparison of Immune-Checkpoint Inhibitors in the Treatment of Metastatic Uveal Melanoma.Journal of clinical medicine · 2025Review
- Article
- Review
- Pathological and Molecular Diagnosis of Uveal Melanoma.Diagnostics (Basel, Switzerland) · 2024Review
- Suicide-Gene-Modified Extracellular Vesicles of Human Primary Uveal Melanoma in Future Therapies.International journal of molecular sciences · 2023Article
- FAK Inhibitor-Based Combinations with MEK or PKC Inhibitors Trigger Synergistic Antitumor Effects in Uveal Melanoma.Cancers · 2023Article
- Discovery of small molecule GActa pharmaceutica Sinica. B · 2022Article
- Glycolysis Dependency as a Hallmark ofCancers · 2022Article
- A Predictive Web-Based Nomogram for Elderly Patients Newly Diagnosed as Uveal Melanoma: A Population-Based Study.Frontiers in medicine · 2022Article
- Case Report:Frontiers in oncology · 2022Article
- An Orthotopic Model of Uveal Melanoma in Zebrafish Embryo: A Novel Platform for Drug Evaluation.Biomedicines · 2021Article
- Review
- Review
- New Therapeutic Perspectives in the Treatment of Uveal Melanoma: A Systematic Review.Biomedicines · 2021Review
- Frequent Subgraph Mining of Functional Interaction Patterns Across Multiple Cancers.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2021Article
- Re-Identification of Patient Subgroups in Uveal Melanoma.Frontiers in oncology · 2021Article
- Emerging roles of microRNAs and their implications in uveal melanoma.Cellular and molecular life sciences : CMLS · 2021Review
- Update on uveal melanoma: Translational research from biology to clinical practice (Review).International journal of oncology · 2020Review
- MicroRNAs and Uveal Melanoma: Understanding the Diverse Role of These Small Molecular Regulators.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Uveal Melanoma (UM) is a rare and malignant intraocular tumor with dismal prognosis. Despite the efficient control of the primary tumor by radiation or surgery, up to 50% of patients subsequently develop metastasis, mainly in the liver. Once the tumor has spread from the eye, the treatment is challenging and the median survival is only nine months. UM represents an intriguing model of oncogenesis that is characterized by a relatively homogeneous histopathological architecture and a low burden of genetic alterations, in contrast to other melanomas. UM is driven by recurrent activating mutations in Gαq pathway, which are associated with a second mutation in BRCA1 associated protein 1 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.